Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,627,370 shares of the medical equipment provider's stock after selling 19,737 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.82% of Zimmer Biomet worth $175,675,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. American Century Companies Inc. increased its position in Zimmer Biomet by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock worth $701,521,000 after purchasing an additional 722,041 shares during the period. Equity Investment Corp purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $70,104,000. Magnetar Financial LLC boosted its stake in shares of Zimmer Biomet by 58.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider's stock worth $142,203,000 after acquiring an additional 484,816 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock worth $391,239,000 after acquiring an additional 411,163 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $41,588,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Evercore ISI decreased their price target on Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 1st. Raymond James decreased their price target on Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. Royal Bank of Canada boosted their price target on Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their price target on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating on the stock in a research note on Monday, September 16th. Finally, Truist Financial upped their target price on Zimmer Biomet from $112.00 to $117.00 and gave the company a "hold" rating in a research note on Friday, November 1st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $123.22.

Zimmer Biomet Trading Up 0.1 %

Shares of ZBH stock traded up $0.08 on Friday, reaching $112.10. 504,058 shares of the stock were exchanged, compared to its average volume of 1,527,881. The stock has a market cap of $22.32 billion, a P/E ratio of 21.31, a price-to-earnings-growth ratio of 2.06 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The firm has a 50 day moving average of $107.29 and a two-hundred day moving average of $109.38. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts' consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.65 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.